2021-2022 Drug Updates in Solid Tumors

Area of Science:

• Oncology
• Pharmacology
• Clinical Practice

Background:

• The landscape of cancer therapeutics is rapidly evolving with frequent regulatory approvals.
• Advanced practitioners require timely updates on new treatments to optimize patient care.

Purpose of the Study:

• To summarize significant Food and Drug Administration (FDA) approvals in oncology from late 2021 to late 2022.
• To discuss the mechanisms of action, clinical utility, and safety profiles of newly approved agents.
• To provide guidance on monitoring strategies for advanced practitioners managing patients with solid tumors.

Main Methods:

• Review of key FDA oncology drug approvals.
• Discussion of unique and expanded mechanisms of action.
• Analysis of safety profiles and monitoring recommendations.

Main Results:

• Key FDA approvals in oncology were presented.
• Mechanisms of action, including unique and transferable ones across malignancies, were detailed.
• Safety profiles and essential monitoring practices for advanced practitioners were outlined.

Conclusions:

• Advanced practitioners were updated on critical late 2021-2022 FDA oncology approvals.
• Understanding novel mechanisms of action and safety is crucial for effective treatment.
• Proactive monitoring is essential for optimizing outcomes in patients with solid tumors.